LivaNova (NASDAQ:LIVN) Stock Price Expected to Rise, Robert W. Baird Analyst Says

LivaNova (NASDAQ:LIVN) had its target price increased by Robert W. Baird from $95.00 to $111.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird‘s target price would suggest a potential upside of 23.35% from the stock’s previous close.

A number of other brokerages also recently weighed in on LIVN. Jefferies Financial Group reaffirmed a “buy” rating on shares of LivaNova in a research report on Wednesday. Raymond James Financial set a $120.00 target price on shares of LivaNova in a report on Wednesday. Needham & Company LLC increased their price target on shares of LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a research report on Wednesday. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a report on Wednesday, August 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.56.

LivaNova Stock Down 1.3%

LIVN stock traded down $1.15 during trading on Thursday, hitting $89.99. 443,974 shares of the company’s stock traded hands, compared to its average volume of 553,701. The firm has a market capitalization of $4.96 billion, a P/E ratio of 30.00 and a beta of 0.91. LivaNova has a 1 year low of $49.73 and a 1 year high of $99.38. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The business has a fifty day simple moving average of $79.27 and a two-hundred day simple moving average of $73.54.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The business had revenue of $393.15 million for the quarter, compared to analysts’ expectations of $381.13 million. During the same quarter last year, the firm earned $1.11 EPS. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Sell-side analysts anticipate that LivaNova will post 3.79 EPS for the current year.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 3,500 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director owned 4,434 shares in the company, valued at approximately $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares in the company, valued at $609,672.96. The trade was a 23.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 7,450 shares of company stock valued at $591,839. 0.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in LivaNova by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock worth $116,067,000 after purchasing an additional 38,320 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of LivaNova by 1,978.8% during the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after buying an additional 448,703 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of LivaNova during the first quarter worth $18,327,000. Sei Investments Co. lifted its stake in shares of LivaNova by 56.6% during the first quarter. Sei Investments Co. now owns 218,805 shares of the company’s stock worth $13,907,000 after buying an additional 79,088 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of LivaNova by 15.7% during the first quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock valued at $11,631,000 after buying an additional 24,900 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.